Tristel, the Cambridgeshire maker of infection prevention products, confirmed on 30 September 2026 that audited results for the year ended 30 June 2026 will be published on Monday 19 October 2026. Its trading update of 22 July 2026 gives a guide to what investors can expect.

Background

Tristel develops disinfectants based on chlorine dioxide chemistry, used to decontaminate medical devices such as ultrasound probes and endoscopes. It is based at Snailwell near Cambridge, employs about 270 people, sells in more than 40 countries and has been quoted on AIM since 2005, under the code TSTL. Its targets are double-digit annual revenue growth, an adjusted EBITDA margin of at least 25% and progressive dividend growth.

What management has already said

In the July update, which was a trading statement rather than audited accounts, Tristel said revenue for the year to 30 June 2026 rose 10% to £51.1m from £46.5m. Adjusted profit before tax was expected to grow 14% to at least £11.5m, compared with £10.1m the year before. The company said the adjusted EBITDA margin was above its 25% target. Cash at 30 June 2026 was £16.0m, against £12.8m a year earlier, and the company reported no debt.

The update also compared these figures with market consensus, which the company put at revenue of £51.1m and adjusted profit before tax of £11.4m. Revenue was therefore in line and profit slightly ahead. Adjusted profit excludes share-based payments, exceptional items and the research and development tax credit, so it will differ from statutory profit.

Anna Wasyl, chief financial officer and interim chief executive, described the year as one of significant growth and said the company continues to meet its target of double-digit annual revenue growth. She also said Tristel remained debt-free and cash-generative.

Leadership change and new product

The more consequential development may be the change at the top. Chris Lee joined as chief executive on 1 August 2026, ending a period in which the finance chief had also been running the business. Mr Lee and Ms Wasyl will give the results presentations on 19 October, his first as chief executive. A product called 3T Pro was commercially launched on 27 July 2026.

Why it matters

The numbers describe a steady compounder rather than a turnaround. Growth of 10% is respectable, and net cash gives room to invest. The test next week will be quality of growth: how much came from the UK, from overseas subsidiaries and from distributors, and whether margins held as costs rose. Those splits were not given in the July statement.

Risks and limitations

The July figures are unaudited and described as at least, so the final outcome could differ modestly. A new chief executive may reset strategy, spending or targets, which can alter the investment case in either direction. Tristel depends on regulatory approvals and healthcare purchasing decisions in many countries, and currency moves affect overseas revenue. The final dividend will be set in the results announcement.